Severe cognitive impairment

Edenred innovates with more sustainable and more inclusive solutions for people with disabilities

Retrieved on: 
Thursday, December 8, 2022
Euronext Paris, FTSE4Good Index, Euronext 100, Recycling, Communication, Disability, Severe cognitive impairment, Language, Maintenance, Ecosystem, App Store (iOS/iPadOS), Huber loss, CAC, Meal voucher, Smartphone, Food, Partnership, Online shopping, Mobile phone, Edenred

Edenred, the leader in earmarked funds solutions in France and worldwide, is enhancing its Ticket Restaurant® and Kadéos solutions.

Key Points: 
  • Edenred, the leader in earmarked funds solutions in France and worldwide, is enhancing its Ticket Restaurant® and Kadéos solutions.
  • These innovations join other features rolled out by Edenred recently such as QR code payment and complementary payments for amounts above available balances.
  • In 2017, Edenred France launched a partnership with Elioz Connect to make its Client Relations Center accessible to the hearing impaired.
  • Ticket Restaurant cards in circulation will be renewed progressively as Edenred replaces expired cards with the new eco-designed versions.

CDR-Life Announces the Appointment of Nicole Onetto, MD, MSc, to Board of Directors

Retrieved on: 
Thursday, December 8, 2022
Roche, Breast cancer, ImmunoGen, Pediatrics, Master of Science, Acquisition, BMS, OSI Pharmaceuticals, Partnership, Bristol Myers Squibb, Ovarian cancer, YM Biosciences, Safety, University, Cancer, Biotechnology, ZymoGenetics, Ontario Institute for Cancer Research, Doctor of Philosophy, Genentech, MD, Geographic atrophy, MHC, Drug development, Severe cognitive impairment, Therapy, Gilead Sciences, Boehringer Ingelheim, Hematology, Senior, Patient, Fine chemical, Pharmaceutical industry, Medicine, Paclitaxel, Pharmacology

We are very pleased to welcome Dr. Nicole Onetto to our Board.

Key Points: 
  • We are very pleased to welcome Dr. Nicole Onetto to our Board.
  • Dr. Onetto previously worked in senior management positions at Bristol Myers Squibb (BMS), Nexstar Pharmaceuticals, and Gilead Sciences.
  • Dr. Onetto holds a medical degree from the University of Paris and a Master of Pharmacology from the University of Montréal.
  • CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, December 7, 2022
Eye, Employment, Inflammation, Graves' ophthalmopathy, Half-life, Pain, Orbit, Fibrosis, Severe cognitive impairment, Financial compensation, Therapy, TED, Patient, Pharmaceutical industry, Viridian

The Inducement Grant has been granted outside of the Company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remains subject to the terms and conditions of such Plan.

Key Points: 
  • The Inducement Grant has been granted outside of the Company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remains subject to the terms and conditions of such Plan.
  • The Inducement Grant was granted as an inducement material to this individual entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grant has an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date.
  • Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies.

Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase

Retrieved on: 
Wednesday, December 7, 2022
NYSE, Environment, New York Stock Exchange, EST, American Academy, AAV, University, Severe cognitive impairment, Therapy, Patient, Pharmaceutical industry

DURHAM, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that Patrick Ritschel, Chief Executive Officer, will present a company overview at the Emerging Life Science Company Showcase hosted by NewYorkBIO and NYSE.

Key Points: 
  • DURHAM, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that Patrick Ritschel, Chief Executive Officer, will present a company overview at the Emerging Life Science Company Showcase hosted by NewYorkBIO and NYSE.
  • The presentation will take place at The New York Stock Exchange on Wednesday, December 14, 2022, at 4:15 p.m. EST.
  • For more information and to register as an in-person or virtual attendee, please click here .
  • Atsena Therapeutics is a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness.

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 6, 2022
Employment, IVT, Neovascularization, Severe cognitive impairment, Research, Standard of care, Patient, Pharmaceutical industry, Adverum Biotechnologies

REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee.
  • On December 1, 2022, Adverum granted a new employee a stock option to purchase 200,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to the employee entering into employment with Adverum.
  • The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on the Nasdaq Stock Market on the grant date, and will vest over four years, subject to the employee’s continued service with Adverum.
  • Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Retrieved on: 
Tuesday, December 6, 2022
Capital commitment, Euronext, SRS, Capital, Disclosure, Sale, Severe cognitive impairment, Cayman, Agreement, DME, EUR, USD, Plasma kallikrein, Diabetic retinopathy, Patient, Term Asset-Backed Securities Loan Facility, Pharmaceutical industry, Security (finance), Limited

Negma Group has converted 80 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.

Key Points: 
  • Negma Group has converted 80 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 311,281,644, outstanding ordinary shares carrying voting rights (compared to 290,273,241 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.
  • Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.

The Centre Pompidou and EnChroma Improve Arts Experience for Colour Blind Visitors

Retrieved on: 
Wednesday, December 14, 2022
Medical Devices, Arts, Museums, Entertainment, Philanthropy, Health, Other Philanthropy, Destinations, Optical, Travel, University of California, Davis, NIH, Lead, Bay, Centraal Museum, Tibbetts Award, Culture, Perception, Severe cognitive impairment, Crystal Bridges Museum of American Art, INSERM, School, Learning, Small business, Prevalence, Collection, SBIR, Museum, Library, Centre Pompidou, Parent, Woman, Garden, Dallas Museum of Art, Chau, Multimedia, Gallerie, Nature, University, Publications Division (India), Common, Economic development, Student, Medical research, Organization, Cosmetics, Entertainment, Art, EnChroma

The Centre Pompidou today announced that colour blind visitors are now able to borrow EnChroma glasses for colour blindness during visits to the iconic museum.

Key Points: 
  • The Centre Pompidou today announced that colour blind visitors are now able to borrow EnChroma glasses for colour blindness during visits to the iconic museum.
  • With over three million annual visitors, an estimated 128,000 guests to the Centre Pompidou are colour blind.
  • While people with normal colour vision see over one million shades and hues of colour, colour blind people see only an estimated 10% of them.
  • The Centre Pompidou is the first museum in France to support the needs of colour blind guests via the EnChroma Colour Accessibility Program .

Sightline by Consilio eDiscovery Platform Achieves WCAG Web Accessibility Certification

Retrieved on: 
Tuesday, December 13, 2022
DEI (Diversity, Equity and Inclusion), Legal, Software, People with Disabilities, Data Management, Professional Services, Technology, Consumer, Certification, WCAG, Element, Person, Diversity, Discovery, HSR, Private law, Disability, Severe cognitive impairment, Minister of Diversity, Inclusion and Youth, Sister Consilio, Sightline, Organization, Online shopping, Internet service provider

Consilio, the global leader of legal technology solutions and enterprise legal services, announced today that it has achieved conformance with the WCAG 2.1 Level AA standard for its leading eDiscovery platform, Sightline by Consilio .

Key Points: 
  • Consilio, the global leader of legal technology solutions and enterprise legal services, announced today that it has achieved conformance with the WCAG 2.1 Level AA standard for its leading eDiscovery platform, Sightline by Consilio .
  • This certification demonstrates that the Companys eDiscovery platform is accessible to a wide range of people with disabilities.
  • Enhancements to the platform ensure Sightline by Consilio is perceivable, operable, and understandable by all users and enables workers with visual and physical disabilities to be more productive.
  • Our goal was to give all Sightline by Consilio users a better product experience by making the platform more accessible while modernizing the interface for all users.

Ophthalmic Diagnostics Equipment Global Market 2022: Focused R&D for Novel Devices Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Medical Devices, Health, Eye disease, Severe cognitive impairment, Approximation error, Ageing, Ophthalmoscopy, Cataract, Vance DeGeneres, AMD, Diagnosis, Corneal ulcers in animals, Prevalence, IgG4-related ophthalmic disease, US, Product type, Macular degeneration, Incidence, World Health Organization, Glaucoma, Keratoconus, End user, Ophthalmology, Growth, WHO, Diabetic retinopathy, Marketing, Region, Medical device, Health insurance

Ophthalmic diagnostic equipment is used for diagnosis of eye disorders such as refractive errors, cataract, and others.

Key Points: 
  • Ophthalmic diagnostic equipment is used for diagnosis of eye disorders such as refractive errors, cataract, and others.
  • Ophthalmic diagnostic equipment constitute of devices such as retinoscopes, visual field analyzers, fundus cameras, ophthalmoscopes, specular microscopes, tonometer, and others.
  • The market for ophthalmic equipment is growing due to the rising incidence of eye disorders and ophthalmic diseases as well as rising healthcare costs.
  • Moreover, increase in prevalence of eye disorders, such as diabetic retinopathy, cataracts, and age-related macular degeneration (AMD), increase in elderly population is also expected to provide lucrative growth to the global ophthalmic diagnostics equipment market.

Verana Health Study of Patients with Dry Age-Related Macular Degeneration Reveals Compelling New Insights Published in International Ophthalmology Journal

Retrieved on: 
Thursday, December 15, 2022
Visual acuity, Physician, EHR, Geographic atrophy, Severe cognitive impairment, HCPS, Data management, HCP, GA, Varnaq, AMD, American Academy, American Academy of Ophthalmology, Macular degeneration, Patient, Vance DeGeneres, American Academy of Neurology, Research, Disease, IRIS, Medicine, Health, Stanford University School of Medicine, Quality of life, Risk, Multimedia, American Urological Association, RWD, SAN, Machine Intelligence Research Institute, Pharmaceutical industry, Publishing, Medical imaging, Therapy, Ophthalmology

SAN FRANCISCO, Dec. 15, 2022 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—today announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has published the results of a study Verana Health conducted to analyze American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight) data for insights into characterizing the most common form of vision loss in the elderly population, age-related macular degeneration (AMD). The study, "Dry Age-Related Macular Degeneration: Distribution of Visual Acuity and Progression Risk in a Large Registry," is a novel study to report on how the stage of disease, as determined by visual acuity (VA), can help predict the risk of progression in dry AMD (dAMD) by stage.

Key Points: 
  • Macular degeneration occurs when a person's retina becomes damaged over time, leading to different levels of vision loss.
  • The study used curated real-world data (RWD) from the Academy IRIS Registrymanaged by Verana Health's VeraQ population health data engineto better understand how patients progress through the stages of dAMD.
  • To request a copy ofthe recently published study, conducted by Dr. Leng and a team of researchers from Verana Health, visit: veranahealth.com/amd-manuscript .
  • Verana Health's quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients.